Suppr超能文献

心房利钠肽与血管紧张素II的肾脏相互作用:对肾小球和肾小管的影响

Renal interaction of atrial natriuretic peptide with angiotensin II: glomerular and tubular effects.

作者信息

Rakugi H, Ogihara T, Nakamaru M, Saito H, Shima J, Sakaguchi K, Kumahara Y

机构信息

Department of Geriatric Medicine, Osaka University Medical School, Japan.

出版信息

Clin Exp Pharmacol Physiol. 1989 Feb;16(2):97-107. doi: 10.1111/j.1440-1681.1989.tb01533.x.

Abstract
  1. The possible interactions between the renal effects of atrial natriuretic peptide (ANP) and angiotensin II (AII) were studied in normal sodium-replete human subjects. Recent investigations have suggested that ANP inhibits the pressor and volume-retaining effects of activation of the renin-angiotensin system. Thus, ANP may attenuate the effects of AII on renal haemodynamics or tubular transport. 2. ANP (0.1 micrograms/kg per min, 60 min) was intravenously infused into eight normal human subjects with and without pretreatment with enalapril (20 mg, per oral), an inhibitor of the converting enzyme, and during infusion of AII (10 mg/kg per min). 3. ANP infusion alone caused increases in the urine volume (from 96 +/- 23 to 229 +/- 44 mL/h, P less than 0.05) and urinary sodium excretion (from 11.5 +/- 1.6 to 20.9 +/- 4.2 mEq/h, P less than 0.05). These changes were accompanied by an increase in the glomerular filtration rate (from 127 +/- 9 to 158 +/- 9 mL/min, P less than 0.05). ANP infusion after enalapril administration lowered the mean blood pressure (from 76 +/- 2 to 71 +/- 3 mmHg, P less than 0.05) to a level similar to that observed during ANP infusion alone (from 84 +/- 2 to 74 +/- 2 mmHg, P less than 0.01), but did not result in a significant diuresis (from 139 +/- 23 to 174 +/- 51 mL/h) or natriuresis (from 19.7 +/- 2.5 to 14.3 +/- 3.4 mEq/h, P less than 0.05). This combined treatment with a converting enzyme inhibitor and ANP reduced both the glomerular filtration rate (160 +/- 9 to 141 +/- 10 mL/min) and the renal plasma flow (from 775 +/- 49 to 570 +/- 45 mL/min, P less than 0.01). 4. The antinatriuretic effects of exogenous AII were reversed by superimposed ANP infusion (urinary sodium excretion: from 4.8 +/- 1.0 to 24.3 +/- 5.2 mEq/h, P less than 0.01). Under these conditions, the glomerular filtration rate increased (from 114 +/- 6 to 156 +/- 7 mL/min, P less than 0.05) to levels similar to those observed with ANP infusion alone. In addition the increased tubular sodium reabsorption induced by AII was inhibited by concomitant ANP infusion (fractional proximal tubular sodium reabsorption: from 90.7 +/- 3.5 to 80.3 +/- 16.6%, P less than 0.05, fractional post-proximal tubular sodium reabsorption: from 91.5 +/- 9.8 to 87.6 +/- 8.8%, P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)
摘要
  1. 在钠摄入充足的正常人类受试者中,研究了心房利钠肽(ANP)和血管紧张素II(AII)对肾脏作用之间可能的相互作用。最近的研究表明,ANP可抑制肾素-血管紧张素系统激活的升压和保钠作用。因此,ANP可能会减弱AII对肾脏血流动力学或肾小管转运的影响。2. 对8名正常人类受试者静脉输注ANP(0.1微克/千克·分钟,共60分钟),其中4名受试者预先口服依那普利(20毫克),一种转换酶抑制剂,同时输注AII(10毫克/千克·分钟)。3. 单独输注ANP导致尿量增加(从96±23毫升/小时增至229±44毫升/小时,P<0.05)和尿钠排泄增加(从11.5±1.6毫当量/小时增至20.9±4.2毫当量/小时,P<0.05)。这些变化伴随着肾小球滤过率增加(从127±9毫升/分钟增至158±9毫升/分钟,P<0.05)。服用依那普利后输注ANP使平均血压降低(从76±2毫米汞柱降至71±3毫米汞柱,P<0.05)至与单独输注ANP时观察到的水平相似(从84±2毫米汞柱降至74±2毫米汞柱,P<0.01),但未导致显著的利尿作用(从139±23毫升/小时增至174±51毫升/小时)或利钠作用(从19.7±2.5毫当量/小时降至14.3±3.4毫当量/小时,P<0.05)。这种转换酶抑制剂与ANP的联合治疗降低了肾小球滤过率(从160±9毫升/分钟降至141±10毫升/分钟)和肾血浆流量(从775±49毫升/分钟降至570±45毫升/分钟,P<0.01)。4. 叠加输注ANP可逆转外源性AII的抗利钠作用(尿钠排泄:从4.8±1.0毫当量/小时增至24.3±5.2毫当量/小时,P<0.01)。在这些条件下,肾小球滤过率增加(从114±6毫升/分钟增至156±7毫升/分钟,P<0.05)至与单独输注ANP时观察到的水平相似。此外,同时输注ANP可抑制AII诱导的肾小管钠重吸收增加(近端肾小管钠重吸收率:从90.7±3.5%降至80.3±16.6%,P<0.05,近端肾小管后段钠重吸收率:从91.5±9.8%降至87.6±8.8%,P<0.05)。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验